Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor (CAR) T-cell therapy can cause immune effector cell-associated neurotoxicity syndrome (ICANS), in which blood-brain barrier (BBB) disruption is a central pathological feature, yet the underlying mechanisms remain poorly understood. Here, we identify indoleamine 2,3-dioxygenase 1 (IDO1)-dependent metabolic reprogramming in cerebrovascular endothelial cells as a mediator linking CAR-T-associated inflammation to BBB dysfunction and neurotoxicity. Patients who developed ICANS exhibited elevated plasma IDO1 activity, a metabolic phenotype recapitulated in a syngeneic CAR-T mouse model characterized by BBB leakage, hippocampal neuronal and synaptic injury, and neurobehavioral impairment. In brain endothelial cells, IDO1 promoted endothelial activation, junctional protein loss, and barrier dysfunction. Pharmacological inhibition and endothelial-specific IDO1 silencing restored barrier integrity and improved neurological outcomes. Mechanistically, IDO1 activation redirected endothelial kynurenine metabolism toward kynureninase (KYNU)-driven anthranilic acid (AA) production, thereby disrupting Wnt/β-catenin-dependent tight junction maintenance. These findings establish the endothelial IDO1-KYNU-AA-Wnt/β-catenin axis as a pathogenic pathway in ICANS and identify endothelial IDO1-dependent metabolism as a potential therapeutic target for preserving BBB integrity and mitigating CAR-T-associated neurotoxicity.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: